Management of psoriasis in children (Review)

Branisteanu,Daciana Elena; Georgescu,Simona; Serban,Ionela Lacramioara; Pinzariu,Alin Constantin; Boda,Daniel; Maranduca,Minela Aida; Glod,Mihai; Branisteanu,Catalina Ioana; Bilibau,Roxana; Dimitriu,Andreea; Nicolescu,Alin Codrut; Branisteanu,Daniel Constantin

doi:10.3892/etm.2021.10864

Management of psoriasis in children (Review)

Authors:
- Daciana Elena Branisteanu
- Simona Georgescu
- Ionela Lacramioara Serban
- Alin Constantin Pinzariu
- Daniel Boda
- Minela Aida Maranduca
- Mihai Glod
- Catalina Ioana Branisteanu
- Roxana Bilibau
- Andreea Dimitriu
- Alin Codrut Nicolescu
- Daniel Constantin Branisteanu
View Affiliations

Affiliations: Department of Dermatology, ‘Grigore T. Popa’ University of Medicine and Pharmacy, 700115 Iasi, Romania, Department of Dermatology, ‘Carol Davila’ University of Medicine and Pharmacy, 050474 Bucharest, Romania, Department of Physiology, ‘Grigore T. Popa’ University of Medicine and Pharmacy, 700115 Iasi, Romania, Department of Surgery, ‘Grigore T. Popa’ University of Medicine and Pharmacy, 700115 Iasi, Romania, ‘Grigore T. Popa’ University of Medicine and Pharmacy, 700115 Iasi, Romania, Department of Dermatology, ‘Railway Clinical Hospital’, 700506 Iasi, Romania, Department of Dermatology, ‘Arcadia Hospitals and Medical Centers’, 700620 Iasi, Romania, Department of Dermatology, Roma Medical Center for Diagnosis and Treatment, 011773 Bucharest, Romania, Department of Ophthalmology, ‘Grigore T. Popa’ University of Medicine and Pharmacy, 700115 Iasi, Romania
Published online on: October 11, 2021 https://doi.org/10.3892/etm.2021.10864
Article Number: 1429
Copyright: © Branisteanu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Psoriasis is a common long‑lasting, inflammatory disease that mainly affects the skin. The incidence of this condition has increased significantly over time and at this point, it affects approximately 1% of children. Psoriasis can appear at any age, including childhood and adolescence, with a higher frequency in girls, an earlier onset being associated with severe psoriasis. The pathology is the result of the interaction between genetics and trigger factors such as infections, stress, diet, obesity, and chemical irritants. Paradoxically, tumor necrosis factor (TNF)‑α inhibitors (infliximab, adalimumab) may induce psoriasis in children. Psoriasis is a long‑term condition with periods of exacerbation; thus, the quality of life can be affected and patients should receive psychosocial support. Although most children have mild disease and topical treatment is efficient, some cases are challenging to treat. The aim of this review was to provide an overview of the current knowledge concerning the epidemiology, etiology, pathogenesis, clinical features, comorbidities, and treatment of psoriasis in children and also to emphasize the need for a multidisciplinary approach to this complex pathology.

View Figures

View References

1	Patterson JW: The psoriasiform reaction pattern. In: Weedon's Skin Pathology. 5th edition. Elsevier, Philadelphia, PA, pp99-120.e11, 2021.
2	Tollefson MM: Diagnosis and management of Psoriasis in children. Pediatr Clin North Am. 61:261–277. 2014.PubMed/NCBI View Article : Google Scholar
3	Kerkhof PCM and van de Nestlé FO: Psoriasis. In: Dermatology. 4th edtion. Philadelphia, PA, pp138-160, 2018.
4	Menter A, Cordoro KM, Davis DMR, Kroshinsky D, Paller AS, Armstrong AW, Connor C, Elewski BE, Gelfand JM, Gordon KB, et al: Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 82:161–201. 2020.PubMed/NCBI View Article : Google Scholar
5	Tkach VY, Voloshynovych MS, Girnyk GY and Kozak NV: Clinical features and the course of psoriasis in children. Przegl Dermatol. 107:476–480. 2020.
6	Tollefson MM, Crowson CS, McEvoy MT and Maradit Kremers H: Incidence of psoriasis in children: A population-based study. J Am Acad Dermatol. 62:979–987. 2010.PubMed/NCBI View Article : Google Scholar
7	Murzina E: Pediatric Psoriasis: Clinical Features and Course. OAJBS. 1(OAJBS.ID.000147)2020.PubMed/NCBI View Article : Google Scholar
8	Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA and Margolis DJ: Prevalence and treatment of psoriasis in the United Kingdom: A population-based study. Arch Dermatol. 141:1537–1541. 2005.PubMed/NCBI View Article : Google Scholar
9	Pinson R, Sotoodian B and Fiorillo L: Psoriasis in children. Psoriasis (Auckl). 6:121–129. 2016.PubMed/NCBI View Article : Google Scholar
10	Parisi R, Symmons DP, Griffiths CE and Ashcroft DM: Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J Invest Dermatol. 133:377–385. 2013.PubMed/NCBI View Article : Google Scholar
11	Paller AS, Singh R, Cloutier M, Gauthier-Loiselle M, Emond B, Guérin A and Ganguli A: Prevalence of psoriasis in children and adolescents in the United States: A claims-based analysis. J Drugs Dermatol. 17:187–194. 2018.PubMed/NCBI
12	Seyhan M, Coşkun BK, Sağlam H, Ozcan H and Karincaoğlu Y: Psoriasis in childhood and adolescence: Evaluation of demographic and clinical features. Pediatr Int. 48:525–530. 2006.PubMed/NCBI View Article : Google Scholar
13	Kwon HH, Na SJ, Jo SJ and Youn JI: Epidemiology and clinical features of pediatric psoriasis in tertiary referral psoriasis clinic. J Dermatol. 39:260–264. 2012.PubMed/NCBI View Article : Google Scholar
14	Ran D, Cai M and Zhang X: Genetics of psoriasis: A basis for precision medicine. Precis Clin Med. 2:120–130. 2019.
15	Paller AS, Siegfried EC, Pariser DM, Rice KC, Trivedi M, Iles J, Collier DH, Kricorian G and Langley RG: Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. J Am Acad Dermatol. 74:280–287.e1-e3. 2016.PubMed/NCBI View Article : Google Scholar
16	Kliegman RM, Geme JWS, Blum NJ, Shah SS, Tasker RC and Wilson KM: Diseases of the epidermis. In: Nelson Textbook of Pediatrics. Kliegman RM and Geme JWS (eds). Elsevier, Philadelphia, PA, pp3501-3510.e1, 2020.
17	Rendon A and Schäkel K: Psoriasis pathogenesis and treatment. Int J Mol Sci. 20(1475)2019.PubMed/NCBI View Article : Google Scholar
18	Batani A, Brănișteanu DE, Ilie MA, Boda D, Ianosi S, Ianosi G and Caruntu C: Assessment of dermal papillary and microvascular parameters in psoriasis vulgaris using in vivo reflectance confocal microscopy. Exp Ther Med. 15:1241–1246. 2018.PubMed/NCBI View Article : Google Scholar
19	Căruntu C, Boda D, Căruntu A, Rotaru M, Baderca F and Zurac S: In vivo imaging techniques for psoriatic lesions. Rom J Morphol Embryol. 55 (Suppl 3):S1191–S1196. 2014.PubMed/NCBI
20	Das RP, Jain AK and Ramesh V: Current concepts in the pathogenesis of psoriasis. Indian J Dermatol. 54:7–12. 2009.PubMed/NCBI View Article : Google Scholar
21	Qing M, Liu P, Zhu W, Chen M, Chen M and Kuang Y: Analysis for 208 children with psoriasis vulgaris. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 45:804–811. 2020.PubMed/NCBI View Article : Google Scholar : (In Chinese, English).
22	Nguyen TT: Papulosquamous eruptions. In: Conn's Current Therapy 2021. Kellerman RD and Rakel D (eds). Elsevier, Philadelphia, PA, pp1056-1061, 2021.
23	Kim SK, Kang HY, Kim YC and Lee ES: Clinical comparison of psoriasis in Korean adults and children: Correlation with serum anti-streptolysin O titers. Arch Dermatol Res. 302:295–299. 2010.PubMed/NCBI View Article : Google Scholar
24	Say M, Boralévi F, Lenormand C, Bursztejn AC, Estève E, Phan A, Bourrat E, Lacour JP, Richard MA, Acher A, et al: Clinical and therapeutic aspects of linear psoriasis: A study of 30 cases. Am J Clin Dermatol. 19:609–615. 2018.PubMed/NCBI View Article : Google Scholar
25	Thomas L, Azad J and Takwale A: Management of nail psoriasis. Clin Exp Dermatol. 46:3–8. 2021.PubMed/NCBI View Article : Google Scholar
26	Uber M, Carvalho VO, Abagge KT, Robl Imoto R and Werner B: Clinical features and nail clippings in 52 children with psoriasis. Pediatr Dermatol. 35:202–207. 2018.PubMed/NCBI View Article : Google Scholar
27	Narla S and Silverberg JI: 15838 Autoimmune comorbidities of psoriasis in US adults and children. J Am Acad Dermatol. 83(AB48)2020.
28	Brandon TG, Manos CK, Xiao R, Ogdie A and Weiss PF: Pediatric psoriatic arthritis: A population-based cohort study of risk factors for onset and subsequent risk of inflammatory comorbidities. J Psoriasis Psoriatic Arthritis. 3:131–136. 2018.PubMed/NCBI View Article : Google Scholar
29	Thomas J and Parimalam K: Treating pediatric plaque psoriasis: Challenges and solutions. Pediatric Health Med Ther. 7:25–38. 2016.PubMed/NCBI View Article : Google Scholar
30	Caruntu C, Boda D, Dumitrascu G, Constantin C and Neagu M: Proteomics focusing on immune markers in psoriatic arthritis. Biomark Med. 9:513–528. 2015.PubMed/NCBI View Article : Google Scholar
31	Brihan I, Hălmăjan A, Boda D, Ianoși SL, Fekete GL and Zdrîncă M: Role of osteodensitometry in osteoporosis and osteopenia in psoriatic arthritis. Exp Ther Med. 20(188)2020.PubMed/NCBI View Article : Google Scholar
32	Taranu T, Constantin M, Ungureanu D, Esanu IM and Toader MP: IL6 is correlated with metabolic syndrome parameters in oral lichen planus. In: 2015 E-Health and Bioengineering Conference (EHB). pp1-4, 2015. http://toc.proceedings.com/29132webtoc.pdf.
33	Brihan I, Ianoși SL, Boda D, Hălmăjan A, Zdrîncă M and Fekete LG: Implications of self-esteem in the quality of life in patients with psoriasis. Exp Ther Med. 20(202)2020.PubMed/NCBI View Article : Google Scholar
34	Gånemo A, Wahlgren CF and Svensson Å: Quality of life and clinical features in Swedish children with psoriasis. Pediatr Dermatol. 28:375–379. 2011.PubMed/NCBI View Article : Google Scholar
35	Branisteanu DC, Stoleriu G, Branisteanu DE, Boda D, Branisteanu CI, Maranduca MA, Moraru A, Stanca HT, Zemba M and Balta F: Ocular cicatricial pemphigoid (Review). Exp Ther Med. 20:3379–3382. 2020.PubMed/NCBI View Article : Google Scholar
36	Karabulut AA, Yalvac IS, Vahaboglu H, Nurozler AB and Duman S: Conjunctival impression cytology and tear-film changes in patients with psoriasis. Cornea. 18:544–548. 1999.PubMed/NCBI
37	Kilic B, Dogan U, Parlak AH, Goksugur N, Polat M, Serin D and Ozmen S: Ocular findings in patients with psoriasis. Int J Dermatol. 52:554–559. 2013.PubMed/NCBI View Article : Google Scholar
38	Cruz NFSD, Brandão LS, Cruz SFSD, Cruz SASD, Pires CAA and Carneiro FRO: Ocular manifestations of psoriasis. Arq Bras Oftalmol. 81:219–225. 2018.PubMed/NCBI View Article : Google Scholar
39	Erbagci I, Erbagci Z, Gungor K and Bekir N: Ocular anterior segment pathologies and tear film changes in patients with psoriasis vulgaris. Acta Med Okayama. 57:299–303. 2003.PubMed/NCBI View Article : Google Scholar
40	Salek SS, Pradeep A, Guly C, Ramanan AV and Rosenbaum JT: Uveitis and juvenile psoriatic arthritis or psoriasis. Am J Ophthalmol. 185:68–74. 2018.PubMed/NCBI View Article : Google Scholar
41	Mahé E: Childhood psoriasis. Eur J Dermatol. 26:537–548. 2016.PubMed/NCBI View Article : Google Scholar
42	Coondoo A, Phiske M, Verma S and Lahiri K: Side-effects of topical steroids: A long overdue revisit. Indian Dermatol Online J. 5:416–425. 2014.PubMed/NCBI View Article : Google Scholar
43	Ogawa E, Sato Y, Minagawa A and Okuyama R: Pathogenesis of psoriasis and development of treatment. J Dermatol. 45:264–272. 2018.PubMed/NCBI View Article : Google Scholar
44	Negrei C, Ginghina O, Caruntu C, Burcea-Dragomiroiu GTA, Jinescu G and Boda D: Investigation relevance of methotrexate polyglutamates in biological systems by high performance liquid chromatography. REV CHIM (Bucharest). 66:766–768. 2015.
45	Negrei C, Caruntu C, Ginghina O, Burcea-Dragomiroiu GTA, Toderescu CD and Boda D: Qualitative and quantitative determination of methotrexate polyglutamates in erythrocytes by high performance liquid chromatography. REV CHIM (Bucharest). 66:607–610. 2015.
46	Boda D, Negrei C, Nicolescu F and Balalau C: Assessment of some oxidative stress parameters in methotrexate treated psoriasis patients. Farmacia. 62:704–710. 2014.
47	Nguyen TU and Koo J: Etanercept in the treatment of plaque psoriasis. Clin Cosmet Investig Dermatol. 2:77–84. 2009.PubMed/NCBI View Article : Google Scholar
48	Branisteanu DE, Voicu CM, Cretu A, Dimitriu A, Luca MC and Salavastru CM: Adverse reactions of biological therapy for psoriasis. Rev Med Chir Soc Med Nat Iasi. 119:38–44. 2015.PubMed/NCBI
49	Papp K, Thaçi D, Marcoux D, Weibel L, Philipp S, Ghislain PD, Landells I, Hoeger P, Kotkin C, Unnebrink K, et al: Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: A randomised, double-blind, phase 3 trial. Lancet. 390:40–49. 2017.PubMed/NCBI View Article : Google Scholar
50	Khobzey K, Liskova I, Szegedi A, Pavlovsky L, Lunder T, Kingo K, Miljković J, Péč J, Bohinc M and Hojnik M: Effectiveness of adalimumab in the treatment of scalp and nail affection in patients with moderate to severe plaque psoriasis in routine clinical practice. Acta Dermatovenerol Alp Pannonica Adriat. 26:11–14. 2017.PubMed/NCBI View Article : Google Scholar
51	Mocanu M, Toader MP, Rezus E and Taranu T: Aspects concerning patient adherence to anti-TNFα therapy in psoriasis: A decade of clinical experience. Exp Ther Med. 18:4987–4992. 2019.PubMed/NCBI View Article : Google Scholar
52	Savage LJ, Wittmann M, McGonagle D and Helliwell PS: Ustekinumab in the treatment of psoriasis and psoriatic arthritis. Rheumatol Ther. 2:1–16. 2015.PubMed/NCBI View Article : Google Scholar
53	Cline A, Bartos GJ, Strowd LC and Feldman SR: Biologic treatment options for pediatric psoriasis and atopic dermatitis. Children (Basel). 6(103)2019.PubMed/NCBI View Article : Google Scholar
54	Broge T, Nguyen N, Sacks A and Davis M: Infliximab-associated psoriasis in children with Crohn's disease may require withdrawal of anti-tumor necrosis factor therapy. Inflamm Bowel Dis. 19:E75–E77. 2013.PubMed/NCBI View Article : Google Scholar
55	Menter MA and Cush JM: Successful treatment of pediatric psoriasis with infliximab. Pediatr Dermatol. 21:87–88. 2004.PubMed/NCBI View Article : Google Scholar
56	Skrabl-Baumgartner A, Weger W, Salmhofer W and Jahnel J: Childhood generalized pustular psoriasis: Longtime remission with combined infliximab and methotrexate treatment. Pediatr Dermatol. 32:e13–e14. 2015.PubMed/NCBI View Article : Google Scholar
57	UCB Celltech: (2018). The Use of Certolizumab Pegol for Treatment of Active Crohn's Disease in Children and Adolescents (NURTURE). ClinicalTrials.gov Identifier: NCT00899678. https://clinicaltrials.gov/ct2/show/NCT00899678.
58	UCB BIOSCIENCES GmbH: (2020). Pediatric Arthritis Study of Certolizumab Pegol (PASCAL). ClinicalTrials.gov Identifier: NCT01550003. https://clinicaltrials.gov/ct2/show/NCT01550003.
59	Novartis Pharmaceuticals: (2020). Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis. ClinicalTrials.gov Identifier: NCT02471144. https://clinicaltrials.gov/ct2/show/NCT02471144.
60	Novartis Pharmaceuticals: (2020). Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis. ClinicalTrials.gov Identifier: NCT03668613. https://clinicaltrials.gov/ct2/show/NCT03668613.
61	Eli Lilly and Company: (2020). Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis (Ixora-peds). ClinicalTrials.gov Identifier: NCT03073200. https://clinicaltrials.gov/ct2/show/NCT03073200.
62	Janssen Research & Development, LLC: (2020). A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants (PROTOSTAR). ClinicalTrials.gov Identifier: NCT03451851. https://clinicaltrials.gov/ct2/show/NCT03451851.
63	Bausch Health Americas, Inc. (2021). An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects. ClinicalTrials.gov Identifier: NCT03240809. https://clinicaltrials.gov/ct2/show/NCT03240809.